ARCALIS is a leading CDMO for mRNA vaccines and therapeutics headquartered in Fukushima, Japan. The company was jointly founded in 2021 by Axcelead and Arcturus Therapeutics, combining their respective expertise in drug discovery and late-stage development. ARCALIS provides drug discovery and nonclinical manufacturing as well as GMP commercial manufacturing and CMC development services for mRNA-based products. Their full-service offering includes mRNA sequence design, analytical testing, LNP formulation preparation, tech transfer, and scale-up.